AB Science is developing two main compounds Masitinib and AB8939

original_735990070

Deliver innovative
therapies in diseases
with high medical need

Two compounds with unique mechanisms of action

Development in 4 therapeutic areas: neurology, oncology, inflammatory diseases and viral diseases

A diversified portfolio including late-stage programs

positive phase 2B/3 readouts with masitinib

publications in peer-reviewed journals

patients enrolled in masitinib studies

Latest news

Boursorama interview of Alain Moussy, CEO of AB Science

December 23, 2020

23/12/2020 – Read the interview of Alain Moussy, CEO of AB Science, in Boursorama

Capital raise for a total amount of 15 million euros

December 21, 2020

21/12/2020 – AB Science announces today the success of its capital raise for a total amount of 15 million euros

Results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease

December 18, 2020

18/12/2020 – AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease

Masitinib in Alzheimer’s Disease Webcast Presentation

December 17, 2020

17/12/2020 – Presentation of the webcast held on December 17, 2020 on masitinib in Alzheimer’s Disease

Results of the Extraordinary General Shareholders’ Meeting of December 16, 2020

December 17, 2020

17/12/2020 – AB Science provides the results of the Extraordinary Shareholders’ Meeting of December 16, 2020

Corrective press release regarding adverse events information from study AB09004

December 17, 2020

17/12/2020 – AB Science issues a corrective press release regarding adverse events information from study AB09004 reported on December 16, 2020